Pharmacokinetics of Enzastaurin HCl in Native Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma

Trial Profile

Pharmacokinetics of Enzastaurin HCl in Native Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Enzastaurin (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 14 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
    • 15 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov.
    • 06 Aug 2015 Planned End Date changed from 1 Sep 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top